Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00104013

NCT00104013
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with probable Alzheimer's disease (based on standard medical guidelines)
  • Your Alzheimer's is considered mild to moderate, shown by a score of 16 to 26 on a standard memory and thinking test called the Mini-Mental Status Examination
  • If you are already taking medication for Alzheimer's disease, you must have been on the same dose for at least 6 months before joining and stay on that same dose throughout the study
  • You have a reliable caregiver and you live either at home in the community or in an assisted living facility
  • Your first language is English, Spanish, or French, and you can read and speak it well
  • You (or your legal representative) and your caregiver are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • Your memory or thinking problems are caused by something other than Alzheimer's disease
  • You have serious health conditions in addition to Alzheimer's disease
  • You have taken part in another medical research study involving an experimental drug in the last two months, or are currently doing so

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Sanofi
Registry
clinicaltrials_gov
Start date
1 November 2003
Est. completion
1 November 2007

Where this trial is recruiting

🇦🇺 Australia 🇫🇷 France Hong Kong 🇮🇹 Italy 🇳🇱 Netherlands 🇸🇬 Singapore 🇿🇦 South Africa 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov